Grifols rises as it reports 7% revenue growth

Shares of Spanish plasma-derived medicines specialist Grifols (MCE: GRF) rose 9% yesterday after it announced results for the first half of 2025, driven by a second quarter marked by continued improvements across key operational and financial metrics. These results reflect the ongoing execution of Grifols’ Value Creation Plan.

Revenues for the first half of the year grew by 7.0% cc to 3,677 million euros ($4.22 billion), driven by the performance of the Biopharma business, which increased by 8.2% at constant currency (cc+. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) reached 876 million euros, up by 12.7% cc year-over-year, representing a 23.8% margin, supported by product mix, continuous improvement initiatives and operational leverage. Net profit surged to 177 million euros, reflecting a 387.6% increase compared to the same period of 2024.

Free cash flow pre-M&A significantly improved to positive 30 million euros in the second quarter, resulting in minus 14 million euros for the first half of the year. This represents a 182 million euros year-over-year improvement, mainly driven by EBITDA growth, working capital management and reduced interest costs.